Eli Lilly Reports First-Quarter 2015 Results
INDIANAPOLIS, April 23, 2015 /PRNewswire/ --
• Revenue declined 1 percent due to the unfavorable impact of foreign exchange rates and the continuing impact of Cymbalta and Evista patent expirations, largely offset by the inclusion of revenue from Novartis Animal Health, higher U.S. prices, and increased volume for several products.
Help employers find you! Check out all the jobs and post your resume.
• Revenue declined 1 percent due to the unfavorable impact of foreign exchange rates and the continuing impact of Cymbalta and Evista patent expirations, largely offset by the inclusion of revenue from Novartis Animal Health, higher U.S. prices, and increased volume for several products.
Help employers find you! Check out all the jobs and post your resume.